White Matter Hyperintensities and Cerebral Amyloidosis: Necessary and Sufficient for Clinical Expression of Alzheimer Disease?
Open accessAbstract
IMPORTANCE: Current hypothetical models emphasize the importance of β-amyloid in Alzheimer disease (AD) pathogenesis, although amyloid alone is not sufficient to account for the dementia syndrome. The impact of small-vessel cerebrovascular disease, visualized as white matter hyperintensities (WMHs) on magnetic resonance imaging scans, may be a key factor that contributes independently to AD presentation. OBJECTIVE: To determine the impact of WMHs and Pittsburgh Compound B (PIB) positron-emission tomography-derived amyloid positivity on the clinical expression of AD. DESIGN: Baseline PIB-positron-emission tomography values were downloaded from the Alzheimer's Disease Neuroimaging Initiative database. Total WMH volume was derived on accompanying structural magnetic resonance imaging data. We examined whether PIB positivity and total WMHs predicted diagnostic classification of patients with AD (n = 20) and control subjects (n = 21). A second analysis determined whether WMHs discriminated between those with and without the clinical diagnosis of AD among those who were classified as PIB positive (n = 28). A third analysis examined whether WMHs, in addition to PIB status, could be used to predict future risk for AD among subjects with mild cognitive impairment (n = 59). SETTING: The Alzheimer's Disease Neuroimaging Initiative public database. PARTICIPANTS: The study involved data from 21 normal control subjects, 59 subjects with mild cognitive impairment, and 20 participants with clinically defined AD from the Alzheimer Disease's Neuroimaging Initiative database. MAIN OUTCOME MEASURES: Clinical AD diagnosis and WMH volume. RESULTS: Pittsburgh Compound B positivity and increased total WMH volume independently predicted AD diagnosis. Among PIB-positive subjects, those diagnosed as having AD had greater WMH volume than normal control subjects. Among subjects with mild cognitive impairment, both WMH and PIB status at baseline conferred risk for future diagnosis of AD. CONCLUSIONS AND RELEVANCE: White matter hyperintensities contribute to the presentation of AD and, in the context of significant amyloid deposition, may provide a second hit necessary for the clinical manifestation of the disease. As risk factors for the development of WMHs are modifiable, these findings suggest intervention and prevention strategies for the clinical syndrome of AD.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The presence of WMH serves as a secondary insult necessary for dementia onset in the context of amyloidosis.
“This aligns with the hypothesis that the presence of WMH serves as a secondary insult necessary for dementia onset in the context of amyloidosis. 34”
From White matter hyperintensity modulates the amyloid‐tau‐cognition association and anti‐amyloid treatment efficacy in asymptomatic older adults (2025) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 53 · Cited by 192
Research works printed but not linked: 1
- [34]Admiraal-Behloul F Olofesen H Van den Heuvel DM Schmitz N Reiber JH Van Buchem MA Fully automated lobe delineation for regional white matter lesion load quantification in a large scale study Proceedings International Society for Magnetic Resonance in medicine 2004 138
- Authors
- Provenzano, F. A., Muraskin, J., Tosto, G., Narkhede, A., Wasserman, B. T., Griffith, E. Y., Guzman, V. A., Meier, I. B., Zimmerman, M. E., Brickman, A. M., & Alzheimer's Disease Neuroimaging Initiative, F. T.
- Affiliations
- Columbia University Irving Medical Center (US)
- Columbia University (US)
- Albert Einstein College of Medicine (US)
- Corresponding author
- Brickman, Adam M.
- ORCID
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2013-04-01
- Volume
- 70
- Issue
- 4
- Pages
- 455
- ISSN
- 2168-6149 (ISSN-L)
- PMC
- PMC4124641
- OpenAlex
- W2128581044
- Cited by
- 192
- References
- 53
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 7 · 2023: 8 · 2022: 17 · 2021: 7 · 2020: 10 · 2019: 21 · 2018: 20 · 2017: 19 · 2016: 11 · 2015: 26 · 2014: 20 · 2013: 16
- FWCI
- 17.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA Neurology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Alzheimer's Association (AG029949, AG034189, AG010129, U01 AG024904)
- Bristol-Myers Squibb (U01 AG024904, AG024904)
- Eli Lilly and Company (U01 AG024904, AG024904)
- Pfizer (AG024904, U01 AG024904)
- AstraZeneca
- Biogen (U01 AG024904, AG024904)
- F. Hoffmann-La Roche (AG024904, U01 AG024904)
- Medpace (U01 AG024904)
- Meso Scale Diagnostics (U01 AG024904, AG024904)
- Synarc (U01 AG024904, P30 AG010129, K01 AG030514)
- Alzheimer's Disease Neuroimaging Initiative (U01AG024904, AG024904, P30 AG010129, K01 AG030514)
- Amorfix Life Sciences
- BioClinica (U01 AG024904, AG024904)
- Novartis Pharmaceuticals Corporation (U01 AG024904, AG024904)
- Northern California Institute for Research and Education (U01 AG024904, K01 AG030514, P30 AG010129)
- Bayer HealthCare
- Eisai (U01 AG024904, AG024904)
- Servier (AG024904, U01 AG024904)
- IXICO (AG024904, U01 AG024904)
- National Institutes of Health (3u01ag024904-10s2, U01-AG024904, AG010129, AG024904, AG034189)
- Genentech (AG024904, U01 AG024904)
- University of California, Los Angeles
- University of California, San Diego
- Canadian Institutes of Health Research (U01 AG024904, K01 AG030514, P30 AG010129)
- National Institute on Aging (U01-AG-024904, P30AG010129, R56AG034189, K01AG030514, AG029949, R01AG034189, AG034189, K23AG029949, U19AG010483)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Neurology › Cerebrovascular and genetic disorders
- Keywords
- white matter hyperintensities, cerebral amyloidosis, Alzheimer's disease, Pittsburgh compound B, amyloid PET, cerebral small vessel disease, mild cognitive impairment, Alzheimer's disease risk prediction, Alzheimer's Disease Neuroimaging Initiative
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Amyloidosis, Aniline Compounds, Brain Mapping, Cerebral Cortex, Female, Humans, Longitudinal Studies, Magnetic Resonance Imaging, Male, Middle Aged, Nerve Fibers, Myelinated, Thiazoles, Databases, Factual, Positron-Emission Tomography, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review